Mirtazapine Grindeks

Mirtazapine, the active ingredient in Mirtazapine Grindeks, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients and is manufactured to EU quality standards under GMP conditions to ensure consistent potency and safety.

GNH USA supplies Mirtazapine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides reliable sourcing, regulatory support and global logistics to meet the needs of healthcare providers across multiple markets.

Mirtazapine is used primarily within the antidepressant therapeutic class to alleviate depressive symptoms.

- Major depressive disorder: reduces depressive mood, improves sleep and appetite, and enhances overall functional capacity. - Depressive episodes associated with major depressive disorder: provides symptom relief when other treatments are insufficient. - Adjunctive therapy for major depressive disorder: used as an add‑on when monotherapy does not achieve desired response.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or worsening depression - Hepatic dysfunction or jaundice - Seizures

When prescribing mirtazapine, clinicians should consider several safety precautions to minimize risk.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor for suicidal ideation: observe patients closely during the first weeks of treatment. - Use caution in the elderly: increased sensitivity to sedation and falls. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Review concomitant CNS depressants: adjust doses to prevent excessive sedation. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a washout period is required. - Other serotonergic antidepressants: may increase serotonin toxicity. - Strong CYP2D6 inhibitors: can raise mirtazapine plasma levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - CNS depressants (alcohol, benzodiazepines): additive sedation. - Warfarin: monitor INR for potential anticoagulant effect changes. - Antihistamines: may enhance sedative properties.